ストックスクリーナーアプリを入手
37.76
45.64%
-31.70
アフターアワーズ：
37.20
-0.56
-1.48%
Vaxcyte Inc (PCVX) 最新ニュース
Vaxcyte: Shares Tanking On Positive Data? Bad Time To Be A Vaccine Developer (NASDAQ:PCVX) - Seeking Alpha
Vaxcyte: Plunge On FDA Top Regulator Resigning Generates Buying Opportunity (NASDAQ:PCVX) - Seeking Alpha
Jefferies maintains Buy on Vaxcyte stock, price target at $146 By Investing.com - Investing.com Australia
Vaxcyte’s VAX-24: Promising Infant Vaccine Results Amidst Investor Concerns - TipRanks
Vaxcyte price target lowered to $90 from $140 at Needham - TipRanks
Vaxcyte ‘narrow’ misses in Phase 2 likely to be ok in Phase 3, says Evercore ISI - TipRanks
Optimistic Outlook for Vaxcyte: Potential for Improved Vaccine Efficacy in Future Trials - TipRanks
Vaxcyte falls as pneumococcal vaccine data fails to meet lofty investor expectations - TradingView
Jefferies maintains Buy on Vaxcyte stock, price target at $146 - Investing.com India
Daily Digest: Large Asian grocer T&T Supermarket to land in S.F.; Vaxcyte stock plunges - The Business Journals
Biotech Stocks Hammered After A Key FDA Official Resigns - Investor's Business Daily
Vaxcyte stock touches 52-week low at $33.19 amid market shifts - Investing.com
Vaxcyte VAX-24 Vaccine Data Missed Wall Street Expectations, But Fundamentally Still Positive, Mizuho Securities Says - MarketScreener
Guggenheim maintains Vaxcyte stock Buy rating, $160 target By Investing.com - Investing.com South Africa
Vaxcyte stock up on results from mid-stage trial of its pneumococcal vaccine - MSN
Guggenheim maintains Vaxcyte stock Buy rating, $160 target - Investing.com India
Vaxcyte reports topline results from VAX-24 infant Phase 2 dose-finding study - TipRanks
Vaxcyte plunges despite pneumonia shot results as Marks departure weighs (PCVX:NASDAQ) - Seeking Alpha
Sector Update: Health Care Stocks Fall Pre-Bell Monday - MarketScreener
Vaxcyte Announces Positive Phase 2 Results for VAX-24 - TipRanks
Vaxcyte Plans To Drop Developing One Pneumococcal Conjugate Vaccine - Benzinga
S&P 500 Futures Fall in Premarket Trading; Vaxcyte, Moderna Lag - Barron's
Vaxcyte's Pneumococcal Conjugate Vaccine Candidate Shows Substantial Immune Response in Infants - Marketscreener.com
Vaxcyte stock tumbles following Phase 2 study results By Investing.com - Investing.com Australia
Vaxcyte Announces Positive Topline Results From VAX-24 Infant Phase 2 Dose-Finding Study - MarketScreener
Vaxcyte stock tumbles following Phase 2 study results - Investing.com
Vaxcyte’s VAX-24 shows promise in infant vaccine study - Investing.com
Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study - GlobeNewswire
Breakthrough: Vaxcyte's New Vaccine Shows Promise in Phase 2 Infant Trial - Stock Titan
Vaxcyte, Inc. (PCVX): One of the Best Debt Free Mid Cap Stocks to Buy Now - Yahoo Finance
Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study - GlobeNewswire
First Look: Vaxcyte Reveals Phase 2 Data for Next-Gen Infant Pneumococcal Vaccine - Stock Titan
Why Vaxcyte, Inc. (PCVX) Is Among the Best Mid Cap Biotech Stocks to Buy - Insider Monkey
Real Estate Deals of the Year: Vaxcyte lease is a Deal of the Year - The Business Journals
Is Vaxcyte, Inc. (PCVX) the Best Up and Coming Stock to Buy According to Wall Street Analysts? - MSN
Vaxcyte (PCVX) Struggled Amid Political Uncertainty - Insider Monkey
Vaxcyte (NASDAQ:PCVX) Is In A Good Position To Deliver On Growth Plans - simplywall.st
Guggenheim Reaffirms Buy Rating for Vaxcyte (NASDAQ:PCVX) - Defense World
Comparing Vaxcyte (NASDAQ:PCVX) and Aptose Biosciences (NASDAQ:APTO) - Defense World
Vaxcyte, Inc. (NASDAQ:PCVX) Shares Bought by Smartleaf Asset Management LLC - Defense World
US Bancorp DE Has $408,000 Stake in Vaxcyte, Inc. (NASDAQ:PCVX) - Defense World
Learn to Evaluate (PCVX) using the Charts - Stock Traders Daily
Vaxcyte’s SVP Mikhail Eydelman sells shares worth $353,699 By Investing.com - Investing.com Australia
Insider Sell: Vaxcyte Inc's COO Jim Wassil Sells 3,000 Shares - GuruFocus.com
Mutual of America Capital Management LLC Lowers Stake in Vaxcyte, Inc. (NASDAQ:PCVX) - Defense World
Bank of New York Mellon Corp Boosts Holdings in Vaxcyte, Inc. (NASDAQ:PCVX) - Defense World
Vaxcyte’s SVP Mikhail Eydelman sells shares worth $353,699 - Investing.com
Vaxcyte, Inc. (NASDAQ:PCVX) Shares Sold by Truist Financial Corp - Defense World
Vaxcyte COO Jim Wassil sells $586,165 in stock By Investing.com - Investing.com Australia
Vaxcyte COO Jim Wassil sells $586,165 in stock - Investing.com India
Vaxcyte, Inc. (PCVX): Among the Cash-Rich Mid Cap Stocks to Buy Now - Insider Monkey
10 Cash-Rich Mid Cap Stocks To Buy Now - Insider Monkey
Vaxcyte phase II PCV valve to open shortly, Pfizer sizers alert - BioWorld Online
Mizuho maintains Vaxcyte stock Outperform rating, $163 target - Investing.com India
(PCVX) Trading Report - Stock Traders Daily
Research Analysts Offer Predictions for Vaxcyte Q1 Earnings - MarketBeat
Vaxcyte, Inc. (NASDAQ:PCVX) Shares Bought by Handelsbanken Fonder AB - MarketBeat
Vaxcyte, Inc. (NASDAQ:PCVX) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Vaxcyte, Inc. (NASDAQ:PCVX) Shares Sold by New York State Common Retirement Fund - Defense World
Q1 Earnings Estimate for Vaxcyte Issued By Leerink Partnrs - Defense World
PCVXVaxcyte, Inc. Latest Stock News & Market Updates - StockTitan
Guggenheim Reiterates "Buy" Rating for Vaxcyte (NASDAQ:PCVX) - MarketBeat
Vaxcyte (NASDAQ:PCVX) Releases Earnings Results, Beats Expectations By $0.14 EPS - MarketBeat
1.05%
1.79%
大文字化:
|
ボリューム (24 時間):